Centessa Pharmaceuticals (NASDAQ:CNTA) Price Target Raised to $43.00

Centessa Pharmaceuticals (NASDAQ:CNTA) had its price objective boosted by Guggenheim from $28.00 to $43.00 in a research report released on Tuesday,Benzinga reports. Guggenheim currently has a buy rating on the stock.

CNTA has been the subject of a number of other reports. Truist Financial set a $30.00 price target on Centessa Pharmaceuticals in a research report on Wednesday, November 5th. Wall Street Zen raised shares of Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, October 27th. Lifesci Capital raised shares of Centessa Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, September 3rd. Oppenheimer began coverage on shares of Centessa Pharmaceuticals in a research note on Friday, August 29th. They issued an “outperform” rating and a $40.00 price objective for the company. Finally, Chardan Capital reaffirmed a “buy” rating and set a $30.00 target price on shares of Centessa Pharmaceuticals in a research note on Tuesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $34.78.

Centessa Pharmaceuticals Stock Down 1.6%

Shares of NASDAQ:CNTA opened at $27.54 on Tuesday. The company has a market cap of $3.70 billion, a price-to-earnings ratio of -15.05 and a beta of 1.56. Centessa Pharmaceuticals has a 12 month low of $9.60 and a 12 month high of $29.33. The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36. The company has a 50-day moving average price of $23.71 and a 200 day moving average price of $17.90.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). As a group, equities research analysts predict that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

Insiders Place Their Bets

In other news, CTO Tia L. Bush sold 40,000 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $26.00, for a total transaction of $1,040,000.00. Following the transaction, the chief technology officer owned 121,503 shares in the company, valued at approximately $3,159,078. This trade represents a 24.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Mario Alberto Accardi sold 8,172 shares of Centessa Pharmaceuticals stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $21.40, for a total value of $174,880.80. Following the completion of the sale, the insider owned 197,394 shares of the company’s stock, valued at $4,224,231.60. The trade was a 3.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 179,964 shares of company stock worth $4,106,481 in the last ninety days. 7.09% of the stock is owned by company insiders.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several large investors have recently modified their holdings of the business. Avoro Capital Advisors LLC boosted its stake in shares of Centessa Pharmaceuticals by 116.2% during the third quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock valued at $262,096,000 after purchasing an additional 5,808,080 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in Centessa Pharmaceuticals by 35.8% during the first quarter. Adage Capital Partners GP L.L.C. now owns 6,954,000 shares of the company’s stock worth $99,999,000 after buying an additional 1,834,973 shares during the period. Federated Hermes Inc. bought a new stake in Centessa Pharmaceuticals during the 3rd quarter valued at $42,429,000. Balyasny Asset Management L.P. bought a new stake in Centessa Pharmaceuticals during the 2nd quarter valued at $16,052,000. Finally, Commodore Capital LP increased its holdings in shares of Centessa Pharmaceuticals by 39.3% in the 2nd quarter. Commodore Capital LP now owns 3,298,289 shares of the company’s stock valued at $43,340,000 after acquiring an additional 930,711 shares during the period. Institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.